{"id":"W4286296171","doi":"10.1200/jco.2022.40.16_suppl.tps11593","title":"TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Pfizer (Canada); Trillium Therapeutics (Canada)","funders":"","keywords":"CD47; Doxorubicin; Medicine; Phagocytosis; Monoclonal antibody; Cancer research; Macrophage; Immune system; Antibody; Internal medicine; Immunology; Chemotherapy; In vitro; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007823141,0.0016948,0.001797462,0.0005440577,0.0003210424,0.001067359,0.0009169953,0.00145446,0.005202841],"category_scores_gemma":[0.0004060368,0.0006472101,0.001456351,0.0005162472,0.0008451741,0.0006944775,0.0003565834,0.002869938,0.001699283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007776375,"about_ca_system_score_gemma":0.001403847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001614613,"about_ca_topic_score_gemma":0.003790217,"domain_scores_codex":[0.9998243,0.00005556141,0.000009382662,0.0000402824,0.00002008436,0.00005025888],"domain_scores_gemma":[0.9996971,0.00002652897,0.00004812213,0.00001758437,0.00002240889,0.0001882342],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3721933,0.1471661,0.006322715,0.003080409,0.002315222,0.0009102904,0.0007332519,0.005712606,0.2106405,0.0008135391,0.01257003,0.2375421],"study_design_scores_gemma":[0.3401151,0.6281213,0.01032342,0.0001189623,0.0008891075,0.000748671,0.0001398236,0.002428267,0.009460976,0.0002851999,0.007301284,0.00006795029],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834453,0.006578027,0.001169528,0.0008639607,0.0002595413,0.002987372,0.001253439,0.0002473156,0.003195506],"genre_scores_gemma":[0.9728757,0.007181906,0.002561027,0.002136132,0.000261889,0.003795109,0.003528381,0.00009597684,0.007563969],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005202841,"threshold_uncertainty_score":0.01740521,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1245483292626334,"score_gpt":0.4765491561945884,"score_spread":0.352000826931955,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}